| ABBV Stock | | | MXN 3,562 26.93 0.76% |
Chairman
Mr. Richard A. Gonzalez is the Chairman of the Board, Chief Executive Officer of the Company. Mr. Gonzalez is the chairman and chief executive officer of AbbVie. He served as Abbott executive vice president of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as president, Abbott Ventures Inc., Abbott medical technology investment arm, from 2009 to 2011. Mr. Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including Abbott president and chief operating officer president, chief operating officer of Abbott Medical Products Group senior vice president and president of Abbott former Hospital Products Division vice president and president of Abbott Health Systems Division and divisional vice president and general manager for Abbott Diagnostics Operations in the United States and Canada. As a result of his service as Abbott executive vice president, Pharmaceutical Products Group, his previous service as Abbott president and chief operating officer and his more than 30year career at Abbott, Mr. Gonzalez has developed valuable business, management and leadership experience, as well as extensive knowledge of AbbVie and its global operations. Mr. Gonzalez experience and knowledge enable him to contribute to AbbVie board key insights into strategic, management, and operational matters. since 2013.
| Age | 69 |
| Tenure | 11 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including: Abbott president and chief operating officer; president, chief operating officer of Abbott Medical Products Group; senior vice president and president of Abbott former Hospital Products Division; vice president and president of Abbott Health Systems Division; and divisional vice president and general manager for Abbott Diagnostics Operations in the United States and Canada.
AbbVie Management Efficiency
The company has return on total asset
(ROA) of
0.0927 % which means that it generated a profit of $0.0927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.7529 %, meaning that it generated $0.7529 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.
AbbVie Inc has accumulated 64.19
B in total debt with debt to equity ratio
(D/E) of 6.52, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AbbVie until it has trouble settling it off, either with new capital or with free cash flow. So, AbbVie's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AbbVie Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AbbVie to invest in growth at high rates of return. When we think about AbbVie's use of debt, we should always consider it together with cash and equity.
Similar Executives
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is based in North Chicago, Illinois. ABBVIE INC operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 48000 people. AbbVie Inc (ABBV) is traded on Mexican Exchange in Mexico and employs 29 people.
Management Performance
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Alban, Executive Vice President - Commercial Operations | |
| Robert Michael, Chief Financial Officer, Senior Vice President | |
| Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | |
| Brett Hart, Independent Director | |
| William Chase, Executive Vice President - Finance and Administration | |
| Roxanne Austin, Independent Director | |
| Perry Siatis, Gen VP | |
| Azita SalekiGerhardt, Executive Vice President - Operations | |
| Scott Reents, VP CFO | |
| Thomas Freyman, Independent Director | |
| Edward Rapp, Independent Director | |
| Richard Gonzalez, Chairman of the Board, Chief Executive Officer | |
| Brian Durkin, Vice President Controller | |
| Frederick Waddell, Independent Director | |
| Robert Alpern, Independent Director | |
| Thomas Hudson, VP Officer | |
| Glenn Tilton, Lead Independent Director | |
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | |
| Elizabeth Shea, VP Relations | |
| Rebecca Roberts, Independent Director | |
| Edward Liddy, Independent Director | |
| William Burnside, Independent Director | |
| Timothy Richmond, Chief Human Resource Officer, Executive Vice President | |
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | |
| Laura Schumacher, Executive Vice President - Business Development, External Affairs, General Counsel | |
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | |
| Melody Meyer, Independent Director | |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to
measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to
predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.